http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 13 Oct 2026 16:05:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Vicore+Pharma+Holding++++++++++++++++++Filed+by%3A+HBM+Healthcare+Investments+%28Cayman%29+Ltd./27181110.html si-local-file:///var/storage/secattach/20261013/27181110.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Vicore+Pharma+Holding++++++++++++++++++Filed+by%3A+HBM+Healthcare+Investments+%28Cayman%29+Ltd./27181110.html Tue, 13 Oct 2026 16:05:00 -0400 VCRE http://www.streetinsider.com/New+Coverage/Jefferies+Starts+Vicore+Pharma+Holding+%28VCRE%29+at+Buy/27168319.html <p>Jefferies analyst Faisal Khurshid initiates coverage on Vicore Pharma Holding (NASDAQ: VCRE) with a Buy rating and a price target of $25.00.</p><p>The analyst comments: “VCRE is a high-risk/high-reward IPF play, but we think the setup into mid-2027 Ph2b ASPIRE data is favorable. Precedent Ph2a AIR data is hard to interpret and almost too good to believe, but we think the synthetic-control analysis, biomarker trends, preclinical work, and MOA rationale all point the same way. Importantly, the bar for ASPIRE is lower than what we saw in AIR: efficacy in line with SOC + clean tolerability should be a win. Initiate http://www.streetinsider.com/New+Coverage/Jefferies+Starts+Vicore+Pharma+Holding+%28VCRE%29+at+Buy/27168319.html Fri, 09 Oct 2026 03:44:26 -0400 VCRE http://www.streetinsider.com/Analyst+Comments/Jefferies+Starts+Vicore+Pharma+Holding+%28VCRE%29+at+Buy/27168319.html <p>Jefferies analyst Faisal Khurshid initiates coverage on Vicore Pharma Holding (NASDAQ: VCRE) with a Buy rating and a price target of $25.00.</p><p>The analyst comments: “VCRE is a high-risk/high-reward IPF play, but we think the setup into mid-2027 Ph2b ASPIRE data is favorable. Precedent Ph2a AIR data is hard to interpret and almost too good to believe, but we think the synthetic-control analysis, biomarker trends, preclinical work, and MOA rationale all point the same way. Importantly, the bar for ASPIRE is lower than what we saw in AIR: efficacy in line with SOC + clean tolerability should be a win. Initiate http://www.streetinsider.com/Analyst+Comments/Jefferies+Starts+Vicore+Pharma+Holding+%28VCRE%29+at+Buy/27168319.html Fri, 09 Oct 2026 03:44:26 -0400 VCRE http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Vicore+Pharma+Holding+++++For%3A+Sep+30/27129358.html si-local-file:///var/storage/secattach/20260930/27129358.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Vicore+Pharma+Holding+++++For%3A+Sep+30/27129358.html Wed, 30 Sep 2026 17:02:00 -0400 VCRE http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Vicore+Pharma+Holding++++++++++++++++/26962377.html si-local-file:///var/storage/secattach/20260821/26962377.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Vicore+Pharma+Holding++++++++++++++++/26962377.html Fri, 21 Aug 2026 17:10:00 -0400 O.03052557 VCRE VICO http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Vicore+Pharma+Holding++++++++++++++++/26962377.html si-local-file:///var/storage/secattach/20260821/26962377.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Vicore+Pharma+Holding++++++++++++++++/26962377.html Fri, 21 Aug 2026 17:10:00 -0400 O.03052557 VCRE VICO http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Vicore+Pharma+Holding++++++++++++++++/26962377.html si-local-file:///var/storage/secattach/20260821/26962377.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Vicore+Pharma+Holding++++++++++++++++/26962377.html Fri, 21 Aug 2026 17:10:00 -0400 O.03052557 VCRE VICO http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Vicore+Pharma+Holding+++++For%3A+Aug+21/26961959.html si-local-file:///var/storage/secattach/20260821/26961959.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Vicore+Pharma+Holding+++++For%3A+Aug+21/26961959.html Fri, 21 Aug 2026 16:42:00 -0400 O.03052557 VCRE VICO http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Vicore+Pharma+Holding+++++For%3A+Aug+21/26961959.html si-local-file:///var/storage/secattach/20260821/26961959.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Vicore+Pharma+Holding+++++For%3A+Aug+21/26961959.html Fri, 21 Aug 2026 16:42:00 -0400 O.03052557 VCRE VICO http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Vicore+Pharma+Holding+++++For%3A+Aug+21/26961959.html si-local-file:///var/storage/secattach/20260821/26961959.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Vicore+Pharma+Holding+++++For%3A+Aug+21/26961959.html Fri, 21 Aug 2026 16:42:00 -0400 O.03052557 VCRE VICO http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Vicore+Pharma+Holding+++++For%3A+Jul+06/26733563.html si-local-file:///var/storage/secattach/20260706/26733563.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Vicore+Pharma+Holding+++++For%3A+Jul+06/26733563.html Mon, 06 Jul 2026 09:17:00 -0400 O.03052557 VCRE VICO http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Vicore+Pharma+Holding+++++For%3A+Jul+06/26733563.html si-local-file:///var/storage/secattach/20260706/26733563.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Vicore+Pharma+Holding+++++For%3A+Jul+06/26733563.html Mon, 06 Jul 2026 09:17:00 -0400 O.03052557 VCRE VICO http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Vicore+Pharma+Holding+++++For%3A+Jul+06/26733563.html si-local-file:///var/storage/secattach/20260706/26733563.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Vicore+Pharma+Holding+++++For%3A+Jul+06/26733563.html Mon, 06 Jul 2026 09:17:00 -0400 O.03052557 VCRE VICO